HIV prevention breakthrough? Twice-Yearly shot could replace daily pills
NCT ID NCT07497594
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study in Brazil offers young men who have sex with men, transgender, and non-binary people a choice between a daily pill or a twice-yearly injection to prevent HIV. Researchers will follow 1,500 participants for up to two years to see how well each option works in real life, how safe it is, and whether people stick with it. The goal is to expand prevention options and make it easier for high-risk groups to stay protected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenacapavir (long-acting injection) and daily oral tenofovir disoproxil fumarate/emtricitabine
What this could lead to
If successful, this could provide a convenient twice-yearly injection option for HIV prevention, potentially improving adherence and reducing new infections among high-risk groups.
What could go wrong
This is an observational study without randomization, so results may be less definitive. Participants choose their own prevention method, which could introduce bias. Long-term safety and effectiveness in real-world settings are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONTACT WITH OR EXPOSURE TO HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
CEDAP - Centro Especializado em Diagnóstico, Assistência e Pesquisa
RECRUITINGSalvador, Estado de Bahia, 40100-010, Brazil
Contact Email: •••••@•••••
-
CTA/Policlínica Centro
RECRUITINGFlorianópolis, Santa Catarina, 88010-400, Brazil
Contact Email: •••••@•••••
-
Centro de Referência e Treinamento em DST/Aids de São Paulo
RECRUITINGSão Paulo, São Paulo, 04121-000, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centro de Referência em IST/Aids de Campinas (SMS/PMC)
RECRUITINGCampinas, São Paulo, 13013-000, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Coordenadoria de IST/Aids da Cidade de São Paulo
RECRUITINGSão Paulo, São Paulo, 01509-020, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fundação de Medicina Tropical Heitor Vieira Dourado
RECRUITINGManaus, Amazonas, 69040-000, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Geral de Nova Iguaçu
RECRUITINGNova Iguaçu, Rio de Janeiro, 26030-380, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Instituto Nacional de Infectologia Evandro Chagas
RECRUITINGRio de Janeiro, Rio de Janeiro, 21040-360, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••